Product Program year 2024 Source: CMS Open Payments

Eloctate

Drug Hematology

NDC 64406-801-01

Open in the dashboard

General payments

$97,766

32 payments

Research payments

$123,764

66 payments

Through program year 2024, $97,766 in general payments and $123,764 in research payments were reported against Eloctate (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Amount Payments
2024 General $24,396 8
2023 General $20,446 4
2022 General $5,918 2
2021 General $2,955 2
2021 Research $2,355 2
2020 General $39,851 15
2020 Research $24,572 5
2019 General $4,200 1
2019 Research $96,837 59

Breakdown

Who paid General payments · program years 2019–2024
  1. Swedish Orphan Biovitrum AB $97,766 32 payments
Top recipients General payments · program year 2024
  1. Lynn Malec Pediatric Hematology-Oncology · Milwaukee, WI $14,682 60% · 2 payments
  2. Robert Sidonio Pediatric Hematology-Oncology · Atlanta, GA $9,715 40% · 6 payments

Each share is of general payments naming this product in 2024.

Specialties paid General payments · program year 2024
  1. Pediatric Hematology-Oncology Pediatrics $24,396 100% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. Wisconsin $14,682 60% · 1 recipient
  2. Georgia $9,715 40% · 1 recipient

Each share is of general payments naming this product in 2024 where a state was reported.

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to ELOCTATE
Billing code Providers Services Paid by Medicare
Injection, factor viii fc fusion protein (recombinant), per iu J7205 1 1,343,306 $2,314,381

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

32 general · 66 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record